Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard of care for patients with metastatic pancreatic ductal adenocarcinoma, noting that pending FDA approval, this effective and tolerable regimen could also inform future clinical trials designs for patients with pancreatic cancer.
New research highlights potential of iOnctura strategy combining autotaxin and TGF-ß inhibitors in cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival.
Geneva, Switzerland, 8 December 2022 iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, announces